E6AA40DA-9AB7-478B-B46B-827F9AFE52D1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 25.88699080157687
- age_years
- 53
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.518
- MYC_TARGETS_V1+0.514
- E2F_TARGETS+0.491
- G2M_CHECKPOINT+0.489
- PROTEIN_SECRETION+0.488
- TGF_BETA_SIGNALING+0.485
- MITOTIC_SPINDLE+0.380
- INTERFERON_ALPHA_RESPONSE+0.378
- INTERFERON_GAMMA_RESPONSE+0.360
- TNFA_SIGNALING_VIA_NFKB+0.358
Top 10 suppressed
- KRAS_SIGNALING_DN-0.381
- MYOGENESIS-0.304
- PANCREAS_BETA_CELLS-0.213
- SPERMATOGENESIS-0.180
- APICAL_SURFACE-0.099
- ESTROGEN_RESPONSE_LATE-0.093
- ESTROGEN_RESPONSE_EARLY-0.050
- APICAL_JUNCTION-0.009
- XENOBIOTIC_METABOLISM-0.003
- COAGULATION+0.027
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.954 |
| 2 | 8B4A5C0E-9F4C-4E4D-B12E-B97666C99707 | — | — | 0.951 |
| 3 | B66ECF23-8CB2-4C95-8E3D-AA63A494F4A0 | — | — | 0.949 |
| 4 | 01169BCB-82ED-4492-9FD0-630CCEA70023 | — | — | 0.947 |
| 5 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.946 |
| 6 | C8955D29-D8EE-4F68-AEAC-CE1B838B22BF | — | — | 0.944 |
| 7 | SRR934827 | — | — | 0.940 |
| 8 | 33060001-05C9-4751-AA58-F194207ACC08 | — | — | 0.938 |
| 9 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.938 |
| 10 | AB522ACF-5D84-41B0-9671-CE2511EBD94F | — | — | 0.932 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.518 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.514 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.491 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.489 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.488 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.485 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.378 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.358 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.351 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.347 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.338 | Inavolisib | — uncovered |
| APOPTOSIS | 0.328 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.304 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.292 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.287 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.276 | Inavolisib | — uncovered |
| COMPLEMENT | 0.272 | Inavolisib | — uncovered |